In this randomized, placebo-controlled, double-blind intervention study, a seven-week intake of a specific synbiotic supplement resulted in a reduction in ALT concentration in metabolically healthy participants, highlighting the possible impact of synbiotics in the disease prevention of obesity and MAFLD due to their potential microbiome-modulating properties. The gene discussed is GPT; the disease is obesity disorder.